Cure Alzheimer’s Fund seeks an entrepreneurial, forward-thinking and collaborative fundraising professional to lead its accomplished development team as Executive Vice President, Development (EVP). Working in concert with senior leadership, development, marketing and research colleagues, the EVP will direct and execute fundraising strategies to contribute significantly to the organization’s vital mission of funding research with the highest probability of preventing, slowing, or reversing Alzheimer’s disease.
With nearly 20 staff and more than 125 researchers around the world, Cure Alzheimer’s Fund has distributed over $87,000,000 to Alzheimer’s research, with many projects resulting in breakthroughs that afford a deeper understanding of Alzheimer’s disease to get closer to a cure. A key breakthrough has included a potential treatment recently selected by the National Institutes of Health for its elite “Blueprint” drug discovery program, and the ground-breaking “Alzheimer’s in a Dish” study, which tested thousands of compounds with the help of artificial intelligence and big data and generated an outcome that promises to greatly accelerate drug testing.
Recognizing that successful drug discovery can only be made possible by attending to foundational research, board directors Henry McCance, Jeffrey and Jacqueline Morby, and Phyllis Rappaport, formed Cure Alzheimer’s Fund in 2004 with an unwavering focus on providing research grants to the world’s leading scientists researching Alzheimer’s disease. The board of directors has also maintained an unwavering commitment to the organization itself by covering all operating expenses, ensuring that every dollar raised goes directly to support research initiatives.
The board’s vision for Cure Alzheimer’s Fund has been carefully and ambitiously designed to accelerate research, make bold bets, and eradicate the disease. To that end, Cure Alzheimer’s Fund has hand-selected a Research Leadership Group that operates under world renowned neuroscientist Dr. Rudolph Tanzi. Dr. Tanzi is credited with co-discovering the first of four Alzheimer’s disease genes. With the support of Cure Alzheimer’s Fund, that number has grown to over 100 identified genes. The Research Leadership Group recommends researchers and reviews proposals from over 65 institutions including Massachusetts General Hospital, Washington University at St. Louis, The University of California at San Diego and Irvine, and The Rockefeller University.
By applying a venture capital business model, Cure Alzheimer’s Fund has been empowered to act proactively and network aggressively in related sub-sectors to identify opportunities and synergies, eliminated bureaucracy for its researchers by creating a fast path to necessary resources, and encourages high risk projects with the potential for transformational discoveries. Additionally, it has knitted together a research community which convenes regularly through quarterly calls and an annual symposium designed for the sharing of ideas and discoveries in order to advance the work.
This bold vision requires a bold approach to fundraising. Historically, Cure Alzheimer’s Fund has relied on individual support, with opportunities to contribute at the major and principal levels, as well as through its Heroes & Heroines and In Memory & In Honor programs. While the organization has experienced 25% annual compound growth into 2018, in large part due to the diligent networking efforts of the Board and the advance of its principal giving program, there is potential for additional systematic growth.
Reporting into the President & CEO, Timothy Armour, the EVP will seek to propel the work of Cure Alzheimer’s Fund by contributing to the full range of fundraising, marketing and outreach activities at the organization’s disposal with the goal of raising significant amounts of philanthropic support for Alzheimer’s-related research, particularly at the principal giving levels.
The EVP will bring dynamic leadership and analytical thinking to the development strategy and process; provide guidance to a dedicated and passionate team of eight development and development operations professionals; personally develop and manage a prospect portfolio of high net worth individuals with direct involvement in the identification, cultivation and solicitation of principal level gifts (six- and seven-figure); and partner with the senior team and Board of Directors to provide input into the organization’s overall strategy and operations.
The successful candidate will possess 7-10 years of progressively responsible development roles including direct frontline fundraising experience, preferably within a complex research-driven and/or academic medical/health center environment. Relationship building skills are critical, as is the ability to become a trusted source of information about Alzheimer’s disease. The candidate will have a proven track record of creating and implementing development strategies with demonstrated success in securing six- and seven-figure gifts. S/he will have managed a staff and worked with volunteer-based support. A broader understanding of campaign development, planned gifts, foundations, and special events is welcome.
A collaborative and accessible leadership style, well-suited to management in a complex environment, is a prerequisite, as is the creativity, energy and political savvy needed to prioritize and champion new ideas. Strong managerial and motivational skills are required, as well as the compassion, clarity, and communication skills necessary to outline clear philanthropic goals and empower the organization’s staff, volunteers, and its most influential supporters. An undergraduate degree is required, and an advanced degree is preferred. The EVP will travel frequently both regionally and nationally.
About Cure Alzheimer's Fund
With nearly 20 staff and more than 125 researchers around the world, Cure Alzheimer’s Fund has distributed over $87,000,000 to Alzheimer’s research, with many projects resulting in breakthroughs that afford a deeper understanding of Alzheimer’s disease to get closer to a cure.